Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.03, Zacks reports.
Eupraxia Pharmaceuticals Stock Up 2.8%
Shares of Eupraxia Pharmaceuticals stock traded up $0.21 during trading hours on Tuesday, reaching $7.63. 475,810 shares of the company were exchanged, compared to its average volume of 388,924. Eupraxia Pharmaceuticals has a 1 year low of $5.63 and a 1 year high of $9.32. The stock’s fifty day moving average is $7.56 and its 200 day moving average is $7.26. The firm has a market cap of $513.04 million, a PE ratio of -7.48 and a beta of 1.04. The company has a debt-to-equity ratio of 0.02, a quick ratio of 16.00 and a current ratio of 16.00.
Wall Street Analysts Forecast Growth
A number of research analysts recently issued reports on EPRX shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Eupraxia Pharmaceuticals in a research report on Thursday, October 8th. Oppenheimer reiterated an “outperform” rating on shares of Eupraxia Pharmaceuticals in a research note on Tuesday, October 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Thursday, October 15th. Stifel Nicolaus set a $25.00 price objective on Eupraxia Pharmaceuticals in a research note on Thursday, September 24th. Finally, Wedbush began coverage on shares of Eupraxia Pharmaceuticals in a report on Thursday, September 24th. They issued an “outperform” rating and a $17.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.17.
Check Out Our Latest Research Report on Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Company Profile
Eupraxia Pharmaceuticals Inc. is a Canadian clinical-stage biopharmaceutical company focused on developing locally delivered therapies for chronic diseases. The company uses its proprietary DiffuSphere technology to formulate drug products designed to provide controlled, sustained release at targeted sites in the body, with the goal of improving treatment effectiveness and tolerability. Eupraxia’s lead development program, EP-262, is an intra-articular therapy being developed for osteoarthritis of the knee.
Featured Stories
- Five stocks we like better than Eupraxia Pharmaceuticals
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
